1. Home
  2. ELVN vs ARI Comparison

ELVN vs ARI Comparison

Compare ELVN & ARI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • ARI
  • Stock Information
  • Founded
  • ELVN 2016
  • ARI 2009
  • Country
  • ELVN United States
  • ARI United States
  • Employees
  • ELVN N/A
  • ARI N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • ARI Real Estate Investment Trusts
  • Sector
  • ELVN Health Care
  • ARI Real Estate
  • Exchange
  • ELVN Nasdaq
  • ARI Nasdaq
  • Market Cap
  • ELVN 1.1B
  • ARI 1.2B
  • IPO Year
  • ELVN 2020
  • ARI 2009
  • Fundamental
  • Price
  • ELVN $16.53
  • ARI $8.35
  • Analyst Decision
  • ELVN Strong Buy
  • ARI Hold
  • Analyst Count
  • ELVN 4
  • ARI 4
  • Target Price
  • ELVN $39.25
  • ARI $9.00
  • AVG Volume (30 Days)
  • ELVN 359.8K
  • ARI 1.4M
  • Earning Date
  • ELVN 05-13-2025
  • ARI 04-24-2025
  • Dividend Yield
  • ELVN N/A
  • ARI 11.98%
  • EPS Growth
  • ELVN N/A
  • ARI N/A
  • EPS
  • ELVN N/A
  • ARI N/A
  • Revenue
  • ELVN N/A
  • ARI $147,887,000.00
  • Revenue This Year
  • ELVN N/A
  • ARI $27.71
  • Revenue Next Year
  • ELVN N/A
  • ARI $4.23
  • P/E Ratio
  • ELVN N/A
  • ARI N/A
  • Revenue Growth
  • ELVN N/A
  • ARI N/A
  • 52 Week Low
  • ELVN $13.30
  • ARI $7.70
  • 52 Week High
  • ELVN $30.03
  • ARI $11.20
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 40.34
  • ARI 36.62
  • Support Level
  • ELVN $15.49
  • ARI $8.13
  • Resistance Level
  • ELVN $18.14
  • ARI $8.46
  • Average True Range (ATR)
  • ELVN 1.93
  • ARI 0.38
  • MACD
  • ELVN -0.17
  • ARI -0.06
  • Stochastic Oscillator
  • ELVN 41.09
  • ARI 32.66

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About ARI Apollo Commercial Real Estate Finance Inc

Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.

Share on Social Networks: